On September 29, 2021 ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, reported its interim results for the six months ended 30 June 2021 (the "Period") (Press release, ImmuPharma, SEP 29, 2021, View Source [SID1234590452]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key Highlights (including post Period review)
Financials
Financial performance in line with expectations over the Period
Cash balance of £4.2m as at 30 June 2021 (31 December 2020: £5.9m)
Loss for the period of £3.7m (30 June 2020: £3m)
Research and development expenses of £1.3m (30 June 2020: £0.9m)
Administrative expenses of £1.5m (30 June 2020: £1m)
Derivative financial asset of £0.2m as at 30 June 2021 (31 December 2020: £1.2m)
Incanthera financial asset of £1.2m (£1.8m at 31 December 2020) and warrants financial asset of £0.2m (£0.6m at 31 December 2020)
Convertible loan notes of £0.7m (£0.6m at 31 December 2020)
Share based expense of £0.3m (30 June 2020: £1m)
Basic and diluted loss per share of 1.46p (30 June 2020: 1.69p)
‘Autoimmunity’: P140
Lupuzor (P140) – now entering a pharmacokinetic ("PK") study prior to the optimized Phase 3 study in lupus in conjunction with its licensing partner, Avion Pharmaceuticals.
P140 for Chronic Inflammatory Demyelinating Polyneuropathy ("CIDP") a neurological disorder targeting the body’s nerves. Active preparation for a phase 2/3 clinical study has now been initiated.
Potential further clinical applications based on further preclinical investigation include asthma, Sjogrens syndrome, renal inflammation in diabetes and periodontitis.
‘Anti-infection’
ioAMB, a novel peptide-based drug that offers a potential improvement on the limiting side effects of current Amphotericin-B ("AMB") formulations. AMB is one of a last line of agents against serious and life-threatening fungal infections caused by the aspergillus family of fungi.
BioCin, a novel peptide-based drug based on an existing potent antibacterial used in high medical need cases. BioCin has the potential to offer improved safety and/or administration benefits.
Board changes
New Board established:
Tim McCarthy appointed as Chief Executive Officer ("CEO")
Dr Tim Franklin appointed as Chief Operating Officer ("COO").
Non Executive Directors ("NED") appointed – Dr Sanjeev Pandya & Lisa Baderoon.